Journal: Oncotarget
Article Title: Gene therapy with plasmids encoding IFN-? or IFN-?14 confers long-term resistance to HIV-1 in humanized mice.
PMID/MRN: 27729616
Publication Date: 2016-Oct-06
Abstract:
Because endogenous interferon type I (IFN-I) produced by HIV-1 infection might complicate the analysis of therapeutically administered IFN-I, we tested different humanized mouse models for induction of IFN-I during HIV-1 infection. While HIV-1 induced high levels of IFN-? in BLT mice, IFN-I was undetectable following infection in the Hu-PBL mouse model, in which only T cells expand. We therefore tested the effect of treatment with Pegylated IFN-2 (pegasys), in Hu-PBL mice. Pegasys prevented CD4 T cell depletion and reduced the viral load for 10 days, but the effect waned thereafter. We next expressed IFN-I subsets (IFN-?2, -?6, -?8, -?14, and -?) in Hu-PBL mice by hydrodynamic injection of plasmids encoding them and 2 days later infected the mice with HIV-1. CD4 T cell depletion was prevented in all subtypes of IFN-I-expressing mice by day 10. However, at day 40 post-infection, protection was seen in IFN-?- and IFN-?14-expressing mice, but not the others. The viral load followed an inverse pattern and was highest in control mice and lowest in IFN-?- and IFN-?14-expressing mice until day 40 after infection. These results show that gene therapy with plasmids encoding IFN-? and -?14, but not the commonly used -?2, confers long-term suppression of HIV-1 replication.